TY - JOUR
T1 - The evolution of factor XI and the kallikrein-kinin system
AU - Ponczek, Michal B.
AU - Shamanaev, Aleksandr
AU - LaPlace, Alec
AU - Dickeson, S. Kent
AU - Srivastava, Priyanka
AU - Sun, Mao Fu
AU - Gruber, Andras
AU - Kastrup, Christian
AU - Emsley, Jonas
AU - Gailani, David
N1 - Funding Information:
This study was supported by a Dean’s Faculty of Biology and Environmental Protection travel subsidy and grant (no. 506/1136) from the University of Lodz, Poland (M.B.P.); Program Grant (RG/12/9/29775) from the British Heart Foundation (J.E.); and a grant from the National Institutes of Health, National Heart, Lung, and Blood Institute (HL140025) (D.G.).
Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/12/22
Y1 - 2020/12/22
N2 - Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to FXIa by factor XIIa (FXIIa), a component, along with prekallikrein and high-molecular-weight kininogen (HK), of the plasma kallikrein-kinin system (KKS). More recent coagulation models emphasize thrombin as a FXI activator, bypassing the need for FXIIa and the KKS. We took an evolutionary approach to better understand the relationship of FXI to the KKS and thrombin generation. BLAST searches were conducted for FXI, FXII, prekallikrein, and HK using genomes for multiple vertebrate species. The analysis shows the KKS appeared in lobe-finned fish, the ancestors of all land vertebrates. FXI arose later from a duplication of the prekallikrein gene early in mammalian evolution. Features of FXI that facilitate efficient FIX activation are present in all living mammals, including primitive egg-laying monotremes, and may represent enhancement of FIX-activating activity inherent in prekallikrein. FXI activation by thrombin is a more recent acquisition, appearing in placental mammals. These findings suggest FXI activation by FXIIa may be more important to hemostasis in primitive mammals than in placental mammals. FXI activation by thrombin places FXI partially under control of the vitamin K-dependent coagulation mechanism, reducing the importance of the KKS in blood coagulation. This would explain why humans with FXI deficiency have a bleeding abnormality, whereas those lacking components of the KKS do not.
AB - Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to FXIa by factor XIIa (FXIIa), a component, along with prekallikrein and high-molecular-weight kininogen (HK), of the plasma kallikrein-kinin system (KKS). More recent coagulation models emphasize thrombin as a FXI activator, bypassing the need for FXIIa and the KKS. We took an evolutionary approach to better understand the relationship of FXI to the KKS and thrombin generation. BLAST searches were conducted for FXI, FXII, prekallikrein, and HK using genomes for multiple vertebrate species. The analysis shows the KKS appeared in lobe-finned fish, the ancestors of all land vertebrates. FXI arose later from a duplication of the prekallikrein gene early in mammalian evolution. Features of FXI that facilitate efficient FIX activation are present in all living mammals, including primitive egg-laying monotremes, and may represent enhancement of FIX-activating activity inherent in prekallikrein. FXI activation by thrombin is a more recent acquisition, appearing in placental mammals. These findings suggest FXI activation by FXIIa may be more important to hemostasis in primitive mammals than in placental mammals. FXI activation by thrombin places FXI partially under control of the vitamin K-dependent coagulation mechanism, reducing the importance of the KKS in blood coagulation. This would explain why humans with FXI deficiency have a bleeding abnormality, whereas those lacking components of the KKS do not.
UR - http://www.scopus.com/inward/record.url?scp=85098071612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098071612&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020002456
DO - 10.1182/bloodadvances.2020002456
M3 - Article
AN - SCOPUS:85098071612
SN - 2473-9529
VL - 4
SP - 6135
EP - 6147
JO - Blood advances
JF - Blood advances
IS - 24
ER -